Skip to main content

The 24-mo Outcomes from the Noninferiority Randomised Controlled Trial of Surgery for Men with Urodynamic Stress Incontinence After Prostate Surgery (MASTER)

In brief

Artificial urinary sphincter cuts repeat surgery to 2% versus 11% with sling

In a 24-month UK trial of 380 men with stress urinary incontinence after prostate surgery, the sling met non-inferiority criteria but the artificial sphincter achieved better continence scores and far fewer re-operations (2% vs 11%). Both procedures markedly improved symptoms, yet the sphincter may offer superior durability, prompting clinicians to weigh higher invasiveness against lower retreatment risk.

Journal
European urology focus (Q1)
Published
26 August 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Lynda Constable, Marcus J Drake, David Cooper, Graeme MacLennan, Chris Harding, Anthony Mundy, et al.
PMID
42648940
DOI
10.1016/j.euf.2026.07.012

Why clinicians should know about it

  • Picked for Urology (top studies of the week, 30 August 2026): Noninferiority RCT of sling vs AUS for post‑prostate SUI

Abstract

BACKGROUND: The artificial urinary sphincter (AUS) is the most common surgical procedure for persistent stress urinary incontinence (SUI) after prostate surgery, whereas the male sling is a newer alternative. OBJECTIVE: To compare the 24-mo outcomes of the sling versus the AUS. DESIGN, SETTINGS, AND PARTICIPANTS: This was an unblinded, noninferiority randomised controlled trial including men from 27 UK urological centres with bothersome urodynamic SUI after prostate surgery. INTERVENTION: Men were randomised to receive a transobturator sling (n = 190) or an AUS (n = 190). Randomisation was minimised by type of surgery (radical prostatectomy/transurethral resection of the prostate), previous radiotherapy for prostate cancer (yes/no), and centre. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was self-reported continence (a composite outcome derived from two items in the validated International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form [ICIQ-UI SF]) at 12 mo after randomisation, with a noninferiority margin of 15%, via postal questionnaire. The secondary outcomes were self-reported continence, further treatments, patient-reported measures and serious adverse events up to 24 mo. RESULTS AND LIMITATIONS: A total of 380 participants were included. In terms of continence, the sling was noninferior to the AUS at 24 mo (estimated absolute risk difference in the intention-to-treat analysis, -0.006; 95% confidence interval [CI], -0.092 to 0.080; noninferiority p = 0.001), indicating lower success in the sling group, but with a CI excluding the noninferiority margin. Incontinence symptom scores (ICIQ-UI SF) decreased from 16.1 and 16.4 at baseline to 7.9 and 7.1 in the sling and AUS groups, respectively. The mean difference was 1.4 (95% CI, 0.2-2.6; p = 0.024). Secondary outcomes favoured the AUS over the sling. By 24 mo, more men underwent further surgery after receiving a sling (n = 20, 11%) than after receiving an AUS (n = 4, 2%). CONCLUSIONS: The 24-mo results confirm that the sling is noninferior to the AUS. Symptoms and quality of life significantly improved in both groups. Overall, secondary and post hoc analyses favour the AUS. PATIENT SUMMARY: Continence levels and symptoms improve with both surgeries. Most men are satisfied with their surgery, despite not being completely dry. Almost all other results show that men who have an artificial urinary sphincter have better outcomes than those who have a sling. Trial registration International Randomised Controlled Trial Registry, ISRCTN49212975. This trial was registered on July 22, 2013, and participants were randomised between January 29, 2014, and December 28, 2017.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.